News

Santé log2h
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
Santé log2h
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
The Company granted options to purchase 325,000 shares, in the aggregate, of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to $3.56, ...
Santé log2h
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders register their shares directly with the Company’s transfer agent, Continental Stock Transfer & ...
Santé log2h
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).
Santé log2h
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).
Santé log2h
IBA lance myQA Blue Phantom³ pour l'assurance qualité en radiothérapie
L'offre de nivellement automatique la plus rapide du marché Intégration aisée avec tous les accélérateurs linéaires Louvain-la-Neuve, Belgique, le 2 mai 2025 – IBA (Ion Beam Applications S.A., EURONEX ...
Santé log2h
Just Blood Uncovers New Blood Testing Technology
In a much-anticipated live demonstration on April 30, 2025, Laboratory expert and entrepreneur Ryan El-Hosseiny shut down Times Square in New York to unveil a new blood testing technology that he ...
Santé log2h
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...
Santé log2h
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to ...
Santé log2h
IBA launches myQA Blue Phantom³ for radiation therapy quality assurance
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a leading provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA ...
Santé log2h
Spectral AI Schedules 2025 First Quarter Financial Results and Conference Call
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at ...
Santé log2h
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help ...